- Drug Shortage Detail: Insulin Glargine Injection (Recombinant) - ASHP
Winthrop has insulin glargine injection available Biocon has insulin glargine-yfgn 3 mL pens and Semglee 3 mL pens available Wholesalers are allocating product Updated June 15, 2025 by Elyse MacDonald, PharmD, MS, BCPS
- Alternative options due to Semglee drug shortage | Blue Cross NC
Blue Cross and Blue Shield of North Carolina (Blue Cross NC) is notifying providers that Semglee (insulin glargine-yfgn) is experiencing a shortage If members are not able to get Semglee at their pharmacy, they can call other pharmacies in the area to try and locate the product
- Back Orders Disrupt National Supply of Select Insulins
Insulin manufacturers, including Novo Nordisk and Biocon, have announced that “short-term manufacturing delays” and “increased demand” have produced shortages of several widely used insulin products
- Semglee Backorder? : r diabetes - Reddit
Is anyone else having trouble getting their Semglee insulin? I have had no problem now for the last year I’ve been using it, but suddenly Walmart (I’m in Arizona) says it’s on manufacturer backorder and they can’t get it from their supplier
- Insulin Shortage Updates, Supply Challenges Solutions
Inadequate insulin supply can be attributed to several potential causes One major factor is the disruption of the supply chain spearheaded by the pandemic, causing logistical nightmares across various industries, including pharmaceuticals
- Ask the FDA: Why Arent the Insulin Biosimilars Coming? What the Hell . . .
Specifically, as of January 4, 2024, the only two FDA-approved biosimilar insulins are as follows: 1 Semglee (insulin glargine-yfgn, 100 Units mL) 2 Rezvoglar (insulin glargine-aglr, 100 Units mL)
- Payer Controls Limiting Semglee Uptake Despite Patient Demand - AJMC
Despite competition from an interchangeable biosimilar and an unbranded generic, branded insulin glargine (Lantus) has kept a hold of not only a majority of total market volume (78%) but also new
- Pharmacy Benefit Managers Are Blocking Patient Access to Biosimilar Insulin
In late 2021, Semglee and its unbranded insulin glargine launched as the first pharmacy-distributed, fully interchangeable biosimilar This is a biosimilar version of the blockbuster diabetes medication, Lantus, and can be substituted at the pharmacy counter
|